High-density lipoprotein cholesterol to apolipoprotein A1 ratio and all-cause mortality among incident peritoneal dialysis patients

2021 ◽  
Author(s):  
Chuanfei Zeng ◽  
Caixia Yan ◽  
Shan Guo ◽  
Hengmei Zhu ◽  
Yanbing Chen ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol ◽  
Dialysis Patients ◽  
All Cause Mortality

scholarly journals Triglyceride to high-density lipoprotein cholesterol ratio is associated with increased mortality in older patients on peritoneal dialysis

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Xiaojiang Zhan ◽  
Mei Yang ◽  
Ruitong Zhou ◽  
Xin Wei ◽  
Yanbing Chen ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Older Patients ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Increased Risk ◽  
All Cause Mortality

Abstract Background The triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) ratio (TG/HDL-C) has been suggested as a simple method to identify unfavorable cardiovascular (CV) outcomes in the general population. The aim of this study was to investigate the association between the TG/HDL-C ratio and all-cause and CV mortality in peritoneal dialysis (PD) patients. Methods We retrospectively analyzed patients on PD from November 1, 2005, to February 28, 2017, with a follow-up period lasting until May 31, 2017. The main outcomes were all-cause and CV mortality. Results Among the 973 PD patients, the mean age was 49.67 ± 14.58 (y). During a median follow-up period of 27.2 months (IQR = 13.4–41.5 months), 229 (23.5%) patients died, with 120 (12.3%) dying as a result of CV diseases. The median serum TG/HDL-C ratio was 1.11 (IQR = 0.71–1.80). In a multivariate Cox regression analysis, patients with higher TG/HDL-C ratio levels (tertile 3) had a higher incidence of CV mortality (adjusted HR = 2.12; 95% CI: 1.21–3.72; P = 0.009) and all-cause mortality (adjusted HR = 2.08; 95% CI: 1.37–3.14; P = 0.001) compared to patients in tertile 1. These associations persisted after excluding the patients who have already taken lipid-lowering medications. For older patients (> 60 years), each 1-unit higher baseline TG/HDL-C level was associated with a 48% (95% CI: 1.06–2.07; P = 0.021) increased risk of all-cause mortality and a 59% (95% CI: 1.03–2.45; P = 0.038) increased risk of CV mortality; however, this association was not observed in patients ≤60 years of age. Conclusions A higher serum TG/HDL-C ratio was an independent predictor of all-cause and CV mortality in PD patients. Furthermore, an elevated TG/HDL-C ratio was significantly associated with higher all-cause and CV mortality in older PD patients.

Combined Detection of Free Fatty Acid (FFA) and High-Density Lipoprotein Cholesterol (HDL-C) is a Promising Pretreatment Biomarker for Predicting the Overall Prognosis (OS) of Neuroendocrine Tumours (NETs) in the Colorectum: A Case-Control Study.

2021 ◽  
Author(s):  
Bin Zhu ◽  
Dan Wu ◽  
Yuanyuan Yang ◽  
Pingli Yu ◽  
Haobo Huang ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Neuroendocrine Tumours ◽  
Tumour Size ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol

Abstract Purpose The aim of the study was to evaluate the prognostic value of free fatty acid (FFA) and high-density lipoprotein cholesterol (HDL-C) in predicting colorectal neuroendocrine tumours (NETs). Methods One hundred patients with pathologically diagnosed colorectal NETs in 2011-2017 were enrolled, and the levels of FFA, HDL-C, low-density lipoproteincholesterol (LDL-C), triglycerides (TGs), cholesterol (CHOL), apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) between colorectal NET patients and healthy controls matched by age and sex were compared. In addition, the association of clinicopathological characteristics and follow-up data with FFA and HDL-C was analysed. Results FFA was overexpressed (0.55±0.23 vs. 0.48±0.11, P= 0.006) and HDL-C was underexpressed (1.31±0.41 vs. 1.41±0.29, P=0.046) in colorectal NETs. FFA ≥0.52 mmol/L predicted lymph node metastasis (LNM) (χ2 = 5.964, P=0.015), and HDL-C ≤1.0 mmol/L predicted tumour size ≥2 cm (χ2 = 5.647, P=0.017). No significant association was found between FFA and tumour size (P=0.142) or HDL-C and LNM (P=0.443). FFA ≥0.52 mmol/L (χ2 = 6.016, P=0.014) and HDL-C ≤1.0 mmol/L predicted worse overall survival (OS) (χ2 = 5.488, P=0.019). FFA ≥0.52 mmol/L in combination with HDL-C ≤1.0 mmol/L predicted an even worse prognosis in terms of OS (χ2 = 4.818, P=0.028). Conclusion FFA ≥0.52 mmol/L and HDL-C ≤1.0 mmol/L were promising cut-off values in predicting LNM, tumour size and worse OS in colorectal NETs.

High-Density Lipoprotein Cholesterol and Left Ventricular Mass Index in Peritoneal Dialysis

2008 ◽  
Vol 28 (6) ◽  
pp. 611-616 ◽  
Author(s):  
Ryota Ikee ◽  
Yoshifumi Hamasaki ◽  
Machiko Oka ◽  
Kyoko Maesato ◽  
Tsutomu Mano ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
High Density Lipoprotein ◽  
Left Ventricular Mass ◽  
High Density Lipoprotein Cholesterol ◽  
Left Ventricular Mass Index ◽  
Density Lipoprotein ◽  
Left Ventricular ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Ventricular Mass Index

Objective The prevalence of left ventricular hypertrophy (LVH) reaches 75% in patients with end-stage renal disease. In patients on peritoneal dialysis (PD), some factors, such as hypertension, volume overload, serum albumin, and residual renal function, have been reported to be related to LVH. Dyslipidemia often occurs in PD but it remains unclear whether dyslipidemia is related to LVH. We investigated the relationship between clinical parameters, including lipid profile, and left ventricular mass index (LVMI). Methods In this cross-sectional study, 34 patients undergoing PD for more than 1 year without combined therapy with hemodialysis were included. We recorded the patients’ clinical data and related those parameters with LVMI as evaluated by echocardiography. Results The patients included 23 males and 11 females (age 62.2 ± 12.1 years, duration on PD 31.6 ± 15.6 months). Mean LVMI was 142 ± 37 g/m2. In univariate analysis, urine volume ( r = -0.493, p = 0.003), total cholesterol ( r = -0.418, p = 0.01), high-density lipoprotein cholesterol (HDL-C; r = -0.374, p = 0.02), and human atrial natriuretic peptide (hANP; r = 0.600, p < 0.001) significantly correlated with LVMI. Stepwise multiple regression analysis showed that hANP (β= 0.524, p = 0.001) and HDL-C (β= -0.422, p = 0.007) were independently associated with LVMI ( r2 = 0.32). Conclusion Strict volume control and salt restriction is essential for prevention of LVH. The role of HDL-C in the development of LVH in PD patients remains to be determined.

Comparison of Intraperitoneal and Subcutaneous Insulin Administration on Insulin Sensitivity and Serum Lipids in Type I Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis Treatment

1995 ◽  
Vol 88 (4) ◽  
pp. 427-432 ◽  
Author(s):  
Jorma T. Lahtela ◽  
Jukka Mustonen ◽  
Amos Pasternack
Keyword(s):  
Peritoneal Dialysis ◽  
Insulin Sensitivity ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Diabetic Patients ◽  
Subcutaneous Insulin ◽  
Intraperitoneal Insulin

1. The metabolic effects of intraperitoneal and subcutaneous insulin delivery were compared in a crossover manner in six C-peptide-negative diabetic patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Each treatment period lasted at least 3 months. Hyperinsulinaemic euglycaemic clamp was performed and glucose turnover assessed using [3-3H]glucose as a tracer. 2. During intraperitoneal delivery the daily insulin dose was 2.4 times higher than during subcutaneous administration and glycaemic control was significantly better (HbA1c 7.63% ± 0.46% and 9.52% ± 0.51% during intraperitoneal and subcutaneous insulin respectively, P < 0.01). The number of hypoglycaemic episodes was lower during intraperitoneal insulin than during subcutaneous therapy. 3. Intraperitoneal insulin resulted in an enhanced glucose disposal rate (P < 0.01) and reduced fasting hepatic glucose production (P < 0.01). High-density lipoprotein-cholesterol decreased and the ratio of low-density lipoprotein/high-density lipoprotein-cholesterol increased significantly (P < 0.05) during intraperitoneal insulin delivery. 4. The results suggest that intraperitoneal insulin, while resulting in better glycaemic control and improved insulin sensitivity than subcutaneous insulin, increases serum triacylglycerol and total cholesterol and reduces high-density lipoprotein-cholesterol, possibly via a direct effect on the liver.

scholarly journals The Association Between Diabetes Coexisting With Low Levels of High-density Lipoprotein Cholesterol and Peritoneal Dialysis-related Peritonitis

2022 ◽  
Author(s):  
Rui Zhang ◽  
Xing Zhang ◽  
Xingming Tang ◽  
Liwen Tang ◽  
Sijia Shang ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
First Episode ◽  
Low Level ◽  
Low Hdl ◽  
Low Levels

Abstract BackgroundLow levels of high-density lipoprotein-cholesterol (HDL-C) and diabetes are common in patients undergoing peritoneal dialysis (PD). The aim of this study was to investigate the association between diabetes coexisting with a low level of HDL-C and the first episode of peritoneal dialysis-related peritonitis (PDRP) in patients with PD.MethodsWe retrospectively investigated patients with PD from January 1, 2003, to May 31, 2020 in four PD centers. Patients with PD were divided into four groups: no comorbidity, low HDL-C only, diabetes only, and diabetes plus low HDL-C. The clinical and laboratory baseline data of the four groups were collected and compared. The association between diabetes coexisting with low HDL-C levels and the first episode of PDRP was analysed by multivariate Cox regression analysis. ResultsA total of 1013 patients with PD were recorded in our study. The mean age was 49.94±14.32 years, and 597 (58.99%) were males. A total of 301 (29.7%) patients had their first episodes of PDRP, and low HDL-C levels existed with diabetes in 72 patients with PD. After adjusting for confounding factors, a low level of HDL-C coexisting with diabetes was significantly associated with the first episode of PDRP in our study (hazard ratio: 1.93, 95% CI: 1.03-3.61, p<0.05). The associations between HDL-C, diabetes and PDRP were consistent in the following subgroups: sex, age, pre-existing CVD (all P interaction > 0.05).ConclusionsLow levels of HDL-C alone or diabetes alone were not independent risk factors for PDRP. Patients with both diabetes and low HDL-C levels were at high risk for PDRP.

scholarly journals Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis

2018 ◽  
Vol 26 (5) ◽  
pp. 533-543 ◽  
Author(s):  
Haris Riaz ◽  
Safi U Khan ◽  
Hammad Rahman ◽  
Nishant P Shah ◽  
Edo Kaluski ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Cardiovascular Mortality ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Cardiovascular Outcomes ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
All Cause Mortality

Background The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. Design We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. Methods Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). Results High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89–1.00, P = 0.05, I2 = 13%) or absolute risk (risk difference −0.0001, 95% CI −0.0014, 0.0011, P = 0.84, I2 = 28%). High-density lipoprotein cholesterol modifiers reduced the RR of myocardial infarction (RR 0.87, 95% CI 0.82–0.93, P < 0.001, I2 = 37%). This significant effect was derived by the use of fibrates (RR 0.80, 95% CI 0.73–0.87, P < 0.001, I2 = 22%) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol. High-density lipoprotein cholesterol modifiers had no effect on stroke (RR 1.00, 95% CI 0.93–1.09, P = 0.94, I2 = 25%) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08, P = 0.48, I2 = 49%). Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints. In studies with background statin therapy, high-density lipoprotein cholesterol modifiers had no statistically significant impact on cardiovascular mortality, myocardial infarction, stroke or all-cause mortality ( P > 0.05). Conclusion The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.

Sign in / Sign up

Export Citation Format

Share Document